home / stock / nbix / nbix articles
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...
A substantial insider activity was disclosed on February 14, as GORMAN, Chief Executive Officer at Neurocrine Biosciences (NASDAQ:NBIX), reported t...
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in...
Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and ado...
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. ...
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in ad...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...
2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $175.00 for NBIX on 2024-05-13 16:13:00. The adjusted price target was set to $175.00. At the time of the announcement, NBIX was trading at $136.15. The overall price target consensus is at $1...
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 PR Newswire CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce...